June 2026
PTSD
What June 2026's 7 new studies found, synthesized from the papers below. All PTSD research →
The synthesis
Synthesized from 7 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for PTSD, post-traumatic stress disorder, traumatic stress, then ranked by relevance.
Research in June 2026 indicates that ketamine-assisted psychotherapy shows promise for PTSD, with more sessions and higher baseline severity predicting greater improvement, though study quality is often poor. MDMA-assisted psychotherapy demonstrates a moderate-to-large effect on PTSD symptoms in RCTs, but concerns about blinding, expectancy effects, and safety monitoring remain. Overall, the evidence is mixed and limited by small samples, heterogeneous designs, and unresolved questions about durability and optimal protocols.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Ketamine-assisted psychotherapy for posttraumatic stress disorder: a systematic review and individual participant data meta-analysis of predictors of treatment effects. 2026 | systematic review and individual participant data meta-analysis | 533 | Supports | Greater improvement in PTSD symptoms was associated with more psychotherapy sessions, more ketamine sessions, higher baseline severity, and shorter treatment duration, but study quality was mostly poor. |
| At-Home Telehealth-Supported Subcutaneous Ketamine Therapy in Adults With Moderate to Severe Depression, Anxiety, or PTSD: A Real-World Observational Study of Safety, Feasibility, and Clinical Outcomes in a Large, Heterogeneous Cohort in the United States. 2026 | observational | 3870 | Supports | At-home telehealth-supported subcutaneous ketamine therapy was safe and feasible, with clinical improvements in PTSD symptoms over 6 weeks. |
| Acute pretrauma ethanol exacerbates PTSD-like phenotype in rats and is reversed by early intranasal ketamine 2026 | preclinical | Supports | Acute ethanol before trauma exacerbated PTSD-like phenotypes in rats, and early intranasal ketamine reversed these effects. | |
| Psychedelic-Assisted Psychotherapy for the Treatment of PTSD: A Systematic Review and Meta-Analysis 2026 | systematic review and meta-analysis | 358 | Mixed | MDMA-assisted psychotherapy showed a significant moderate-to-large reduction in PTSD symptoms, while the pooled effect for ketamine was small and non-significant, and a single cannabidiol trial showed no clear benefit. |
| Investigational drugs in PTSD. 2026 | review | Supports | Ketamine produces symptom reductions within hours, and MDMA-assisted psychotherapy has demonstrated Phase 3 efficacy, but questions remain about durability, optimal dosing, and long-term safety. | |
| From therapeutic promise to evidentiary discipline: Reassessing MDMA-assisted psychotherapy for posttraumatic stress disorder. 2026 | commentary | Unclear | MDMA-assisted psychotherapy shows therapeutic promise but is constrained by difficulties in blinding, expectancy effects, lack of active comparators, and limited mechanistic clarity. | |
| The impact of ketamine on posttraumatic stress disorder (PTSD) symptomatology in trauma-exposed populations: a narrative review. 2026 | narrative review | Mixed | Some studies indicate ketamine provides rapid PTSD symptom relief, while others raise concerns about its contribution to dissociative states and maladaptive memory consolidation. |
Greater improvement in PTSD symptoms was associated with more psychotherapy sessions, more ketamine sessions, higher baseline severity, and shorter treatment duration, but study quality was mostly poor.
systematic review and individual participant data meta-analysis Sample size: 533
At-home telehealth-supported subcutaneous ketamine therapy was safe and feasible, with clinical improvements in PTSD symptoms over 6 weeks.
observational Sample size: 3870
Acute ethanol before trauma exacerbated PTSD-like phenotypes in rats, and early intranasal ketamine reversed these effects.
preclinical
MDMA-assisted psychotherapy showed a significant moderate-to-large reduction in PTSD symptoms, while the pooled effect for ketamine was small and non-significant, and a single cannabidiol trial showed no clear benefit.
systematic review and meta-analysis Sample size: 358
Ketamine produces symptom reductions within hours, and MDMA-assisted psychotherapy has demonstrated Phase 3 efficacy, but questions remain about durability, optimal dosing, and long-term safety.
review
MDMA-assisted psychotherapy shows therapeutic promise but is constrained by difficulties in blinding, expectancy effects, lack of active comparators, and limited mechanistic clarity.
commentary
Some studies indicate ketamine provides rapid PTSD symptom relief, while others raise concerns about its contribution to dissociative states and maladaptive memory consolidation.
narrative review
Points of agreement
- Ketamine and MDMA are the most studied psychedelic agents for PTSD.
- Ketamine-assisted psychotherapy shows rapid symptom reduction in some studies.
- MDMA-assisted psychotherapy demonstrates promising efficacy in RCTs.
- Higher baseline PTSD severity is associated with greater improvement in ketamine studies.
Conflicts
- The meta-analysis found a small non-significant effect for ketamine, while other studies report significant symptom reduction.
- Some observational studies link ketamine to heightened dissociation and hyperarousal, while clinical trials report no lasting dissociative effects.
- MDMA-assisted psychotherapy shows strong efficacy in some trials but is criticized for methodological limitations like poor blinding and expectancy effects.
Gaps
- Durability of treatment effects beyond short-term follow-up is unclear.
- Optimal dosing, number of sessions, and patient selection criteria are not established.
- Long-term safety data, especially for repeated ketamine use, are lacking.
- Most studies lack active comparator conditions and robust blinding.
- Sample sizes are small, and generalizability to diverse populations is limited.
- Mechanisms of action for psychedelic-assisted psychotherapy remain poorly understood.